Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 37 Gynecologic 2 Tumor-Agnostic 1 Other 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1

Conditions

Interventions

pembrolizumab 26 Specimen Handling 22 Biopsy 22 Magnetic Resonance Spectroscopy 20 Paclitaxel 12 Carboplatin 10 Blood Specimen Collection 10 Bevacizumab 10 atezolizumab 9 Standard of Care 9 Nivolumab 9 Cisplatin 8 Radiosurgery 7 Pemetrexed 7 Gemcitabine 6 Cyclophosphamide 6 Capecitabine 6 trastuzumab deruxtecan 5 durvalumab 5 X-Rays 5 Taxes 5 Surveys and Questionnaires 5 Irinotecan 5 Fluorouracil 5 olaparib 4 niraparib 4 cabozantinib 4 Radiotherapy 4 Oxaliplatin 4 Leucovorin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

exemestane × Tumor-Agnostic × 90 days × Clear all

NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡